Stocks · Healthcare · Biotechnology
INmune Bio, Inc. INMB
$1.93 +0.00% Close, Oct 2, 2026 · NASDAQ · Market cap $51.3M
Expensive vs sectorHigh risk
Next earnings report: Oct 29, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 14.7% in a year.
- The stock is in an uptrend: above its 200-day average for 68 trading days, with the 50-day average above the 200-day.
- Earnings beat analyst estimates in each of the last 4 quarters (average surprise over the last four: +37.5%).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
- Revenue growth, 3-year CAGRBottom 3%
- Revenue growth accelerationTop 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 11%
- Accruals (lower is better)Top 26%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 20%
- Free-cash-flow yieldBottom 15%
- EBITDA / enterprise valueBottom 11%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 42%
- 6-month returnTop 16%
- 1-year return vs S&P 500Bottom 36%
- Distance from 52-week highTop 40%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 15%
- Consecutive EPS beatsTop 19%
- Share of analysts rating BuyBottom 34%
- Upside to consensus price targetTop 2%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 27%
- Maximum drawdown, 3 yearsBottom 11%
- Beta vs S&P 500 (lower is better)Bottom 38%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -100.0% | -100.0% | → |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | -100.0% | → | Bottom 2% |
| Return on invested capital | -92.8% | — | Bottom 11% | |
| Revenue growth, 3-year CAGR | -48.9% | — | Bottom 3% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -12.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +221.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.59%
- Shareholder yield
- -1.59%
- Share count change, 1 year
- +14.7%
- Share count change, 3-year CAGR
- +14.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 4
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +37.5%
- Average 2-day reaction, last 8
- -1.7%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $22.00
- Target vs current price
- +1039.9%
- Analysts with a rating
- 9
- Share rating Buy or Strong Buy
- 67%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +75.8% | +0.5% | +7.4% | +23.7% | — |
| May 7, 2026 | +18.4% | -5.9% | -3.9% | -11.2% | +21.7% |
| Mar 30, 2026 | +33.3% | +1.8% | +9.8% | +31.2% | +20.5% |
| Oct 30, 2025 | +22.6% | -4.9% | -2.7% | -9.3% | -1.1% |
| Aug 7, 2025 | -183.8% | +1.1% | -7.2% | -30.4% | -37.3% |
| May 8, 2025 | +0.0% | -0.7% | +4.1% | +2.9% | -59.9% |
| Mar 27, 2025 | +25.9% | -4.1% | +4.4% | +4.0% | -19.5% |
| Oct 31, 2024 | -22.4% | -1.7% | +8.1% | -17.8% | +52.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.05 | -$0.21 | +75.8% | — |
| May 7, 2026 | -$0.20 | -$0.25 | +18.4% | — |
| Mar 30, 2026 | -$0.18 | -$0.27 | +33.3% | — |
| Oct 30, 2025 | -$0.24 | -$0.31 | +22.6% | — |
| Aug 7, 2025 | -$1.05 | -$0.37 | -183.8% | — |
| May 8, 2025 | -$0.43 | -$0.43 | +0.0% | $50,000 |
| Mar 27, 2025 | -$0.40 | -$0.54 | +25.9% | — |
| Oct 31, 2024 | -$0.60 | -$0.49 | -22.4% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -31.77% | — | — | Bottom 15% |
| Earnings yield | -35.75% | — | — | Bottom 20% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 68
- 50-day average slope (20 days)
- +7.6%
- 200-day average slope (20 days)
- +2.6%
- Distance from 50-day average
- -8.8%
- Distance from 200-day average
- +17.9%
- RSI (14)
- 39.5
- Relative volume
- 0.82×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 71.6%
- Volatility vs own 5-year history
- 30th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.32
- Correlation with S&P 500
- 0.26
- Current drawdown from 1-year high
- -23.1%
- Maximum drawdown, 3 years
- -92.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 7, 2021 | Mar 27, 2026 | -96.0% | 1143 days | Not yet recovered |
| Jan 19, 2021 | May 13, 2021 | -65.4% | 80 days | 80 days (Sep 7, 2021) |
| Sep 25, 2020 | Nov 2, 2020 | -32.3% | 26 days | 36 days (Dec 23, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $51.3M
- EPS, diluted (TTM)
- -$0.69
- Revenue (TTM)
- $0
- 52-week range
- $1.09 – $2.60
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $181,000 | $374,000 | $155,000 | $14,000 | $50,000 |
| Gross profit | $181,000 | $374,000 | $155,000 | $14,000 | $50,000 |
| Operating income | -$29.2M | -$26.0M | -$29.7M | -$42.6M | -$30.9M |
| Net income | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| EPS (diluted) | -$1.88 | -$1.52 | -$1.67 | -$2.11 | -$1.86 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $50,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.1M | -$9.2M | -$9.7M | -$24.5M | -$6.5M | -$5.3M | -$5.4M | -$1.3M |
| EPS (diluted) | -$0.60 | -$0.41 | -$0.43 | -$1.05 | -$0.24 | -$0.20 | -$0.20 | -$0.05 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$28.5M | -$22.7M | -$12.0M | -$33.4M | -$22.6M |
| Capital expenditure | -$15.0M | $0 | $0 | $0 | -$1.0M |
| Free cash flow | -$43.5M | -$22.7M | -$12.0M | -$33.4M | -$23.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $80.3M | $699,000 | $775,000 | $27.8M | $27.6M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $18.4M
- Total assets
- $26.8M
- Total liabilities
- $6.5M
- Total debt
- $1.4M
- Net debt
- -$17.0M
- Shareholders’ equity
- $20.4M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 2,251,105
- Days to cover
- 7.78
- Change vs previous report
- +3.1%
FINRA short interest, settlement date Sep 15, 2026.